It may be time to meet with your radiologist to review your myeloma imaging tests. Imaging technologies have advanced greatly in the past few years and have become a new and important vehicle for diagnosis and prognosis. Dr. Jens Hillengass is a world renown expert on imaging techniques in multiple myeloma and shares his key learning about the technology in this show. He first shares that the traditional x-ray or skeletal survey does not provide as much information as the CT scan. Work is now being done by the International Myeloma Working Group to make CT the new gold standard over x-ray. He shares the importance of PET and MRI to see inside of the bone marrow and discusses the important use of MRI to identify unique patterns of lesions in the bone marrow: focal lesions, diffuse infiltration and a salt and pepper pattern. The number of lesions and the presence of the diffuse infiltration pattern are important for prognosis based on his research. He tells us that about a third of patients have focal lesions only and another third have diffuse only while the last third have both. If patients have more than 7 focal lesions, a dense diffuse pattern or both focal lesions and the diffuse infiltration, they have worse prognosis, but that prognosis needs to bear in mind a holistic view of each patient that also looks at LDH levels, cytogenetics and imaging results together. He gives recommendations about what imaging techniques newly diagnosed patients should receive and also shares his important recommendations for smoldering myeloma patients. This is a key show for patients who want to take charge of their care and know what questions to ask their doctor for their most accurate diagnosis and prognosis. The Myeloma Crowd Radio Show with Dr. Jens Hillengass, MD
Jens Hillengass, MD, PhD, is Professor of Oncology and Chief of the Myeloma and Amyloidosis Service at Roswell Park Cancer Institute in Buffalo, NY. Prior to joining Roswell, he was the deputy of the section multiple myeloma of the University Hospital of Heidelberg, Germany, the leader of its autologous stem cell transplantation program, and head of the hemato-oncological imaging research group at the German Cancer Research Center (DKFZ). He completed his medical degree at Heidelberg University, where he later completed residency and fellowship in the department of hematology, oncology, and rheumatology. Dr Hillengass received a Gerok scholarship to study radiology at the German Cancer Research Center. Additionally, he completed a research fellowship at the National Cancer Institute. Dr. Hillengass is member of the Black Swan Research Initiative of the International Myeloma Foundation and the International Myeloma Working Group where he co-chairs the bone and imaging group.
Myeloma survivor, patient advocate, wife, mom of 6. Believer that patients can help accelerate a cure by weighing in and participating in clinical research. Founder of the HealthTree Foundation.
Thank you for your interest in the event. If you have any questions, we would love to help!
Feel free to give us a call or send us a message below.
+1 800 709 1113
Support@healthtree.org
Subscribe to the weekly "HealthTree Community for Myeloma Newsletter" for Myeloma news, life with Myeloma stories, Myeloma clinical trials, Myeloma 101 articles and events with Myeloma experts.